AbstractMucosal antibodies play a key role in protection against breakthrough COVID‐19 infections and emerging viral variants. Intramuscular adenovirus‐based vaccination (Vaxzevria) only weakly induces nasal IgG and IgA responses, unless vaccinees have been previously infected. However, little is known about how Vaxzevria vaccination impacts the ability of mucosal antibodies to induce Fc responses, particularly against SARS‐CoV‐2 variants of concern (VoCs). Here, we profiled paired mucosal (saliva, tears) and plasma antibodies from COVID‐19 vaccinated only vaccinees (uninfected, vaccinated) and COVID‐19 recovered vaccinees (COVID‐19 recovered, vaccinated) who both received Vaxzevria vaccines. SARS‐CoV‐2 ancestral‐specific IgG antibodies capable of engaging FcγR3a were significantly higher in the mucosal samples of COVID‐19 recovered Vaxzevria vaccinees in comparison with vaccinated only vaccinees. However, when IgG and FcγR3a engaging antibodies were tested against a panel of SARS‐CoV‐2 VoCs, the responses were ancestral‐centric with weaker recognition of Omicron strains observed. In contrast, salivary IgA, but not plasma IgA, from Vaxzevria vaccinees displayed broad cross‐reactivity across all SARS‐CoV‐2 VoCs tested. Our data highlight that while intramuscular Vaxzevria vaccination can enhance mucosal antibodies responses in COVID‐19 recovered vaccinees, restrictions by ancestral‐centric bias may have implications for COVID‐19 protection. However, highly cross‐reactive mucosal IgA could be key in addressing these gaps in mucosal immunity and may be an important focus of future SARS‐CoV‐2 vaccine development.